Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 27, 2020
Daily News
May 27, 2020
- Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
- Fujifilm Eyes FY2020 Trial Launch for Liposome Drug-Keytruda Combo
May 27, 2020
- Shionogi Snaps Up Tetra after PII Alzheimer’s Study Completed
May 27, 2020
- Bayer’s Prostate Cancer Med Nubeqa Now Available in Japan
May 27, 2020
- Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
May 27, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Council to Discuss Medical Needs for Additional Indications for Antiemetics Ondansetron, Granisetron
May 27, 2020
- Japan Pharma Market Tops 10 Trillion Yen for 5th Year Running in FY2019, Keytruda Surges to No.1: IQVIA
May 27, 2020
- Japan Pharma Market Up 0.2% in January-March: IQVIA
May 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…